TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

ALBUTEROL SULFATE
Respiratory Approved 2007-12-31
1
Indication
--
Phase 3 Trials
18
Years on Market

Details

Status
Prescription
First Approved
2007-12-31
Routes
INHALATION
Dosage Forms
SOLUTION

Companies

Active Ingredient: ALBUTEROL SULFATE , IPRATROPIUM BROMIDE

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Approval History

Loading approval history...

What ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Treats

2 indications

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE is approved for 2 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bronchospasm
  • Obstructive Airway Disease
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE FDA Label Details

Pro

Indications & Usage

Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. 1.1 Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate HFA is indicated for t...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.